Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNITE-Larynx: Becotatug Vedotin + Pucotenlimab Neoadjuvant Therapy for Locally Advanced Laryngeal Cancer
ChiCTR2600120886Phase 2Not yet recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin and pucotenlimab in laryngeal squamous cell carcinoma (LSCC), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: One-year larynx preservation rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
laryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on ChiCTR2600120886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120886.